Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Interpace Diag Group (IDXG)

Interpace Diag Group (IDXG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Interpace Biosciences Announces First Quarter 2020 Financial and Business Results

First Quarter Net Revenue Improved Over 53% to $9.2 Million

IDXG : 5.17 (-0.77%)
Interpace Biosciences to Host Conference Call and Webcast to Discuss First Quarter, 2020 Financial Results on Thursday June 25, 2020

Interpace Biosciences (IDXG) announced today that it will report its first quarter, 2020 financial results on Thursday, June 25, 2020 at 4:30 p.m. ET. Interpace will host a conference call and webcast...

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces Contract with Lab Benefits Management Firm

In-Network Access for More Than 3 Million Members

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results

Conference Call and Webcast Wednesday April 22, 2020 5:00 pm ET

IDXG : 5.17 (-0.77%)
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020

Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company management will host a conference call and webcast to discuss...

IDXG : 5.17 (-0.77%)
Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts

Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced today that it has entered into a contract with Blue Cross Blue Shield of Massachusetts. While terms of this Agreement...

IDXG : 5.17 (-0.77%)
Interpace Diagnostics Announces Contract with BCBS of Massachusetts

In-Network Access for More Than 3 Million Members

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company's ThyGeNEXT and ThyraMIR tests in the Journal of the American...

IDXG : 5.17 (-0.77%)
Interpace Announces Extension of LabCorp Agreement

ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years

IDXG : 5.17 (-0.77%)
LH : 172.68 (-0.25%)
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement for Interpace Diagnostics' ThyraMIR miRNA classifier for...

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership

-- Ron Rocca, CEO of Exagen, appointed to Board

IDXG : 5.17 (-0.77%)
XGN : 10.62 (+0.57%)
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners

Reverse Stock Split Planned Concurrent with Closing

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN(R) after Ablation of Dysplastic Barrett's Esophagus

Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company's wholly-owned subsidiary, Interpace Diagnostics has entered into a collaborative...

IDXG : 5.17 (-0.77%)
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT(R)

Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company's ThyGeNEXT test,...

IDXG : 5.17 (-0.77%)
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China

Further Strengthens Business Development Team with Key Hire

IDXG : 5.17 (-0.77%)
Interpace Biosciences Launches New Corporate Website

Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, "Interpace.com". Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented...

IDXG : 5.17 (-0.77%)
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

Third Quarter Revenue Grew 34% Over the Prior Year's Quarter and 25% Year to Date

IDXG : 5.17 (-0.77%)
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019

Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss...

IDXG : 5.17 (-0.77%)
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility

Clinical Data Highlights the Utility of ThyGeNEXT and ThyraMIR

IDXG : 5.17 (-0.77%)
Interpace to Present Data at the ATA Annual Meeting

Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89 Annual Meeting of the American Thyroid Association (ATA), being...

IDXG : 5.17 (-0.77%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.29 , SEDG +2.26 , THC +0.97 , TER -1.08 , LITE -1.41
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar